Z
Zi-Ming Zhao
Researcher at Yale University
Publications - 20
Citations - 934
Zi-Ming Zhao is an academic researcher from Yale University. The author has contributed to research in topics: Cancer & Gene. The author has an hindex of 10, co-authored 19 publications receiving 653 citations. Previous affiliations of Zi-Ming Zhao include Georgia Institute of Technology & Miami University.
Papers
More filters
Journal ArticleDOI
Single-molecule paleoenzymology probes the chemistry of resurrected enzymes
Raul Perez-Jimenez,Alvaro Ingles-Prieto,Zi-Ming Zhao,Inmaculada Sanchez-Romero,Jorge Alegre-Cebollada,Pallav Kosuri,Sergi Garcia-Manyes,T. Joseph Kappock,Masaru Tanokura,Arne Holmgren,Jose M. Sanchez-Ruiz,Eric A. Gaucher,Eric A. Gaucher,Julio M. Fernandez +13 more
TL;DR: It is concluded that ancient Trxs use chemical mechanisms of reduction similar to those of modern enzymes, which have adapted over 4 Gyr to the changes in temperature and ocean acidity that characterize the evolution of the global environment from ancient to modern Earth.
Journal ArticleDOI
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
Humam Kadara,Murim Choi,Murim Choi,J. Zhang,Edwin Roger Parra,Jaime Rodriguez-Canales,Stephen G. Gaffney,Zi-Ming Zhao,Carmen Behrens,James G. Fujimoto,Chi-Wan Chow,Yongjin Yoo,Neda Kalhor,Cesar A. Moran,David L. Rimm,S.G. Swisher,Don L. Gibbons,John V. Heymach,Edward Kaftan,Jeffrey P. Townsend,Thomas J. Lynch,Joseph Schlessinger,Je Sang Lee,Richard P. Lifton,Richard P. Lifton,I. I. Wistuba,Roy S. Herbst +26 more
TL;DR: This study performs whole-exome sequencing and immune profiling analyses of a unique set of clinically annotated early-stage LUADs to better understand the pathogenesis of this disease and identify clinically relevant molecular markers.
Journal ArticleDOI
Early and multiple origins of metastatic lineages within primary tumors.
Zi-Ming Zhao,Bixiao Zhao,Yalai Bai,Atila Iamarino,Stephen G. Gaffney,Joseph Schlessinger,Richard P. Lifton,David L. Rimm,Jeffrey P. Townsend +8 more
TL;DR: T tumor phylogenetics is performed using molecular evolutionary models, reconstructed ancestral states of somatic mutations, and inferred cancer chronograms to yield three conclusions, one of which is that in contrast to a linear model of cancer progression, metastases can originate from divergent lineages within primary tumors.
Journal ArticleDOI
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.
Xing Yi Woo,Jessica Giordano,Anuj Srivastava,Zi-Ming Zhao,Michael Lloyd,Roebi de Bruijn,Yun-Suhk Suh,Rajesh Patidar,Li Chen,Sandra D. Scherer,Matthew H. Bailey,Chieh-Hsiang Yang,Emilio Cortes-Sanchez,Yuanxin Xi,Jing Wang,Jayamanna Wickramasinghe,Andrew V. Kossenkov,Vito W. Rebecca,Hua Sun,R. Jay Mashl,Sherri R. Davies,Ryan Jeon,Christian Frech,Jelena Randjelovic,Jacqueline Rosains,Francesco Galimi,Andrea Bertotti,Adam Lafferty,Alice C. O’Farrell,Elodie Modave,Diether Lambrechts,Petra ter Brugge,Violeta Serra,Elisabetta Marangoni,Rania El Botty,Hyun Soo Kim,Jong Il Kim,Han-Kwang Yang,Charles Lee,Dennis A. Dean,Brandi N. Davis-Dusenbery,Yvonne A. Evrard,James H. Doroshow,Alana L. Welm,Bryan E. Welm,Michael T. Lewis,Bingliang Fang,Jack A. Roth,Funda Meric-Bernstam,Meenhard Herlyn,Michael A. Davies,Li Ding,Shunqiang Li,Ramaswamy Govindan,Claudio Isella,Jeffrey A. Moscow,Livio Trusolino,Annette T. Byrne,Jos Jonkers,Carol J. Bult,Enzo Medico,Jeffrey H. Chuang +61 more
TL;DR: In this paper, the authors exhaustively analyzed copy number alterations in 1,451 PDX and matched patient tumor (PT) samples from 509 PDX models, and they showed strong CNA conservation from PTs through late-passage PDXs.
Journal ArticleDOI
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function
Murim Choi,Murim Choi,Humam Kadara,Jianhua Zhang,Edwin Roger Parra,Jaime Rodriguez-Canales,Stephen G. Gaffney,Zi-Ming Zhao,Carmen Behrens,James G. Fujimoto,Chi-Wan Chow,K. Kim,Neda Kalhor,Cesar A. Moran,David L. Rimm,S.G. Swisher,Don L. Gibbons,John V. Heymach,Edward Kaftan,Jeffrey P. Townsend,Thomas J. Lynch,Joseph Schlessinger,J. Jack Lee,Richard P. Lifton,Richard P. Lifton,Roy S. Herbst,I. I. Wistuba +26 more
TL;DR: Analysis of mutations with immune markers revealed that ADCY8 and PIK3CA mutations were associated with markedly decreased tumoral PD-L1 expression, LUSCs with PIK 3CA mutations exhibited elevated CD45ro levels and CDKN2A-mutant tumors displayed an up-regulated immune response.